ASLAN Pharmaceuticals (ASLN)
(Delayed Data from NSDQ)
$0.43 USD
-0.03 (-5.88%)
Updated Jun 4, 2024 09:49 AM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
Price, Consensus and EPS Surprise
ASLN 0.43 -0.03(-5.88%)
Will ASLN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ASLN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ASLN
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
ASLN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now
Other News for ASLN
Aslan Pharmaceuticals Amends Loan Conversion Terms
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
Aslan Pharmaceuticals presents data on eblasakimab as ATS conference
Piper Sandler Remains a Buy on Aslan Pharmaceuticals (ASLN)
ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024